Dana-farber Cancer Institute
Clinical trials sponsored by Dana-farber Cancer Institute, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Prehab for rectal cancer: could a simple program boost recovery? Results expected Sep 2026 (estimated)
- New hope for aggressive uterine cancer: targeted drug trial shows promise Results expected Sep 2026 (estimated)
- Exercise may tame steroid side effects in stem cell transplant patients Results expected Sep 2026 (estimated)
- Acupuncture needles take on chemo nerve pain in major trial Results expected Sep 2026 (estimated)
- Zoom bike workouts could help young brain tumor survivors get fit and think sharper Results expected Sep 2026 (estimated)
-
Triple oral drug combo targets two stubborn gynecologic cancers
Disease control Not yet recruitingResearchers are testing a combination of three oral drugs, imlunestrant, abemaciclib, and selinexor, in people with low grade serous ovarian cancer or endometrioid endometrial cancer. The trial enrolls 60 participants in two separate groups, one for each cancer type. Everyone rec…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Blood test could guide cancer treatment, reducing side effects
Disease control Not yet recruitingThis study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to tailor myeloma treatment to each patient
Disease control Not yet recruitingThis Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cocktail aims to tame myeloma without transplant
Disease control Not yet recruitingThis study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug aims to shrink rare adrenal tumors
Disease control Not yet recruitingThis phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the dru…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New program aims to boost medication adherence for breast cancer patients in rwanda
Disease control Not yet recruitingThis study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how …
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug targets rare lung cancer subtype in early trial
Disease control Not yet recruitingThis phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Tumor profiling may unlock targeted drug options for pediatric cancers
Diagnosis Not yet recruitingThis study tests whether a two-step tumor profiling approach can reliably measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid or central nervous system tumors. The approach uses bulk RNA sequencing to screen for tar…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a simple blood test spot hidden cancers? new study aims to find out
Diagnosis Not yet recruitingThis study will test the GRAIL Galleri blood test, which looks for signs of many different cancers in a single blood draw. Researchers will enroll 100 adults who have symptoms that might be cancer. The goal is to see how well the test detects cancer and how it compares to standar…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Could a 'Baby Dose' of hormone pills prevent breast cancer?
Prevention Not yet recruitingThis study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Can a video game teach cancer patients to tame their pain?
Symptom relief Not yet recruitingResearchers at Dana-Farber Cancer Institute are testing Healing Gardens, a mobile game that delivers pain-focused cognitive behavioral therapy and cancer pain education. The study enrolls 46 adults with advanced solid tumors who have chronic pain related to cancer or its treatmen…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can an AI app give a voice to brain tumor patients?
Symptom relief Not yet recruitingThis trial tests whether a smartphone app called LISTEN can help people with brain tumors who have trouble speaking (aphasia) communicate more easily. The app uses artificial intelligence to adapt to each user's needs and can be used with voice input and output. Researchers will …
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A cool wristband takes on hot flashes — no drugs needed
Symptom relief Not yet recruitingThis trial tests whether a wearable device that delivers a cooling sensation on the wrist can reduce the burden of hot flashes in men with prostate cancer who are on androgen deprivation therapy (ADT). About 66 participants will be randomly assigned to use the device right away o…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
New app aims to ease cancer pain at home
Symptom relief Not yet recruitingThis study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New program aims to improve sexual Well-Being in women with advanced breast cancer
Symptom relief Not yet recruitingThis study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health issues. About 96 women will take part in group video sessions or receive an informational booklet. The goal is to see if the program improves sexual …
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Digital tests may offer a new way to track brain health in tumor patients
Knowledge-focused Not yet recruitingThis study explores whether self-administered digital cognitive tests can accurately measure thinking skills like attention, memory, and processing speed in people with primary central nervous system lymphoma or low-grade gliomas. Participants will complete both digital tests (on…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Can storytelling and support groups break the stigma around cancer in rwanda?
Knowledge-focused Not yet recruitingThis study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stig…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New app guides young cancer survivors through life after treatment
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New algorithm aims to boost nutrition and quality of life for cancer patients
Knowledge-focused Not yet recruitingThis study aims to create a nutrition algorithm called NACHO that suggests foods and recipes tailored to cancer patients' needs. Researchers will work with dietitians, clinicians, and patient advisors to develop the tool, then test it with 130 patients who are undergoing or have …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC